Comparing two drugs for sleep in dialysis patients with itch
Treatments studied
Part of Immune system & allergy, Kidney & urinary, Lungs & breathing, Women’s health & pregnancy clinical trials.
This trial tests if anrikefon or nalfurafine improves sleep quality in people on hemodialysis who have chronic kidney disease-related itching. It aims to find a better treatment for both itch and sleep problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- You get regular hemodialysis 3 times a week for end-stage kidney disease.
- You have had itchy skin for at least 6 weeks, with itching on most days.
- Your worst itching in the past week was moderate to severe (score 4 or more on a 0–10 scale).
- You have trouble sleeping (score above 7 on a sleep quality test).
- You have not used certain medications like opioids, gabapentin, pregabalin, or sleep aids recently.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a special blood-filtering device (hemoadsorption) to your regular dialysis treatment can reduce uncomfortable symptoms caused by kidney failure, like fatigue or itching. Researchers will track how you feel over time compared to standard dialysis alone.
This trial tests if a medication called nalfurafine hydrochloride (taken as a tablet that melts in your mouth) can help reduce moderate to severe itching in people receiving peritoneal dialysis for chronic kidney disease.
This study tests a new oral medication, nalfurafine hydrochloride, to see if it helps reduce itching in people on dialysis. It might offer a new option for those whose current itch treatments haven't been effective.
This study tests a medication called nalfurafine to see if it can reduce severe itching (pruritus) that often comes with advanced kidney disease in people on dialysis. If you have moderate to severe itching and have been on dialysis twice a week for more than 6 months, this trial may offer a potential new treatment option.
This trial tests a drug called difelikefalin to see if it safely reduces moderate-to-severe itching in teenagers who are on hemodialysis. Itching is common in kidney disease, and this study aims to find a new treatment option.
This trial tests a drug called difelikefalin to see if it can reduce severe itching in people on hemodialysis for chronic kidney disease. If you have troublesome itching despite dialysis, this treatment might help relieve it.
Hear when a new Renal Insufficiency, Chronic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.